A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

What Was Tested

The trial (phase 1) is built around Cagrilintide and CagriSema (Cagrilintide + Semaglutide).

The purpose of this clinical study is to compare 2 different versions cagrilintide and see how these work in people living with excess body weight.

Participant will get either cagrilintide B or cagrilintide D injections.

Which treatment participant will get is decided by chance.

It had two arms (groups): Cagrilintide B (experimental) and Cagrilintide D (experimental).

Participants will receive cagrilintide B subcutaneously once weekly for 5 weeks.

Participants will receive cagrilintide D subcutaneously once weekly for 5 weeks.

The registry classes the interventions as drug.

Who Took Part

The registry lists 50 actual participants took part.

It was open to people of any sex aged from 18 years up to 64 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18-64 years (both inclusive) at the time of signing informed consent. Male or female (sex assigned at birth). Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.

The full record lists 4 inclusion and 3 exclusion criteria; among the exclusions: any condition, unwillingness or inability which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol (a); as declared by the participant, reported in the medical records or at the investigator's discretion.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

Because people in this Cagrilintide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Nothing was hidden in this open-label Cagrilintide study: the participants and staff both knew the treatment.

It started in 2026-05-20 with completion listed for 2026-08-19.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Cagrilintide and CagriSema (Cagrilintide + Semaglutide) in 50 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Cagrilintide compound page and the CagriSema (Cagrilintide + Semaglutide) compound page, all human trials.